top glp-1 companies Latin America Glucagon-like Peptide-1 (GLP-1) Agonists GLP-1 agonists market to reach
Description
Peaka GLP-1 is a dietary supplement, not an FDA-approved medication
In Phase 3 clinical trials completed in December 2025, retatrutide produced an average body weight reduction of 28.7% at the highest dose over 68 weeks
Osteoporosis in anorexia nervosa
The Three Receptors: What Each One Does Retatrutide's three target receptors each contribute a distinct metabolic function: GLP-1R reduces appetite and slows gastric emptying, GIPR enhances insulin secretion and glucose handling, and GCGR increases hepatic energy mobilisation and fatty acid oxidation
From endocrine to rheumatism: do gut hormones play roles in rheumatoid arthritis
